Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms Combi-Neo
- 14 Feb 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
- 14 Feb 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 07 Jun 2017 Status changed from recruiting to active, no longer recruiting, according to the results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology